22.08.2022 - (PLX AI) – Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes.Novo Nordisk says CagriSema reduces blood sugar more than semaglutide alone and the weight loss seen in the trial confirms the substantial .